



**Vaccines and Global Health: The Week in Review**  
**2 May 2020 :: Number 551**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is also **posted in pdf form** and as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 8,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request an email version:*** *Vaccines and Global Health: The Week in Review is published as a single email summary, scheduled for release each Saturday evening at midnight (EST/U.S.). If you would like to receive the email version, please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

F. [Media Watch](#)



## ***Milestones :: Perspectives :: Research***

.....  
.....

### **COVID-19 & Global Immunization**

#### **Geneva Palais briefing note on the impact of COVID-19 mitigation measures on vaccine supply and logistics**

GENEVA, 1 May 2020 – **“UNICEF is calling for support to unlock a massive backlog in vaccine shipments due to unprecedented logistical constraints related to COVID-19 mitigation measures including lockdowns in some countries.**

“In 2019, UNICEF procured 2.43 billion doses of vaccines for 100 countries, to reach approximately 45 per cent of all children below five years old.

**“Since the week of March 22, UNICEF has seen a 70 - 80 per cent reduction in planned vaccine shipments due to the dramatic decline in commercial flights and limited availability of charters.**

**“As of today, dozens of countries are at risk of stock-out due to delayed vaccine shipments. At most risk are 26 countries that are difficult to reach due to limited commercial and cargo options. Among these, at least five countries experienced measles outbreaks in 2019 and many more remain at risk.**

“Compounding the challenge is the exorbitant cost of securing flights, with freight rates at 100 - 200 per cent above normal and charter flights even more costly.

“Countries with limited resources will struggle to pay these higher prices, leaving children vulnerable to vaccine-preventable diseases such as measles and polio.

“Even before the COVID-19 pandemic, measles, polio and other vaccines were out of reach for 20 million children below the age of one every year.

“Disruptions in routine immunization, particularly in countries with weak health systems, could lead to disastrous outbreaks in 2020 and well beyond.

“A substantial proportion of the vaccines that are not reaching countries as planned are for routine immunization programmes. Because of the delays, countries have been using buffer stocks, which typically consists of a three-month supply that is intended for unplanned and urgent needs including responding to sudden outbreaks. As transport challenges persist, countries are at increasing risk of a vaccine stock-out.

“The extended delays in shipments also pose a huge risk to manufacturers, who must store the excess vaccine stocks, and may be required to postpone future production if their warehouse storage space is exceeded.

“UNICEF is working to find solutions with manufacturers and partners, including WHO, GAVI, the vaccine alliance, PAHO and the Bill and Melinda Gates Foundation. Some manufacturers have offered to support with their freight forwarding services, and GAVI has provided additional funding to support charter flights. And we continue to work with governments to monitor their stock levels, prioritize the most critical vaccine shipments to avoid stockouts and respond to the needs of their immunization programmes.

“However, the logistical situation remains severely constrained. And many countries require additional funding support.

“UNICEF is appealing to governments, the private sector, the airline industry, and others, to free up freight space at an affordable cost for these life-saving vaccines. And to work with us to find ways around the transport disruptions we face. Children’s lives are at stake.”

*Press release*

**Disruption of childhood vaccination in South Asia poses an urgent threat to children’s health – UNICEF**

*4.5 million of South Asia’s children miss out on routine immunization, even before COVID-19*  
28/04/2020

KATHMANDU, 28 April 2020 – South Asia could face yet another health emergency if children across the region do not receive their life-saving vaccine shots, UNICEF warned today.

Almost a quarter of the world’s unimmunized or partially immunized children—about 4.5 million children—live in South Asia. Almost all of them, or 97 per cent, live in India, Pakistan and Afghanistan. **With lockdowns in place as a part of the novel coronavirus (COVID-19) response, routine immunizations have been severely disrupted, and parents are increasingly reluctant to take their children to health centers for routine jabs. Sporadic outbreaks of vaccine-preventable diseases, including measles and diphtheria, have already been seen in parts of Bangladesh, Pakistan and Nepal.**

The South Asia region is also home to two of the last polio endemic countries in the world, Afghanistan and Pakistan.

“Vaccine stocks are running dangerously low in some countries of the region as supply chains have been disrupted with travel bans and cancelled flights. The manufacturing of the vaccines has also been disrupted, creating additional shortages,” says Paul Rutter, Regional Health Advisor for UNICEF Regional Office for South Asia (ROSA).

Many of the health facilities throughout the region, where millions of children are normally vaccinated, have been closed and outreach sessions have been suspended, adding to the challenge.

“As long as frontline health workers take the appropriate precautions, particularly washing their hands, there is no reason not to vaccinate – in fact, it is crucial that vaccination continues,” says Paul Rutter.

Across the region, national mass vaccination campaigns have been postponed. Bangladesh and Nepal have postponed their national measles and rubella campaigns while Pakistan and Afghanistan have suspended their polio campaigns.

UNICEF strongly recommends that, where immunization campaigns are suspended, governments begin rigorous planning now to intensify immunization activities once the COVID - 19 pandemic is under control.

"We are very concerned about the impact of not getting children vaccinated," says Jean Gough, Director of UNICEF ROSA. "Many of these children are already vulnerable. While the COVID-19 virus does not appear to make many children seriously ill, the health of hundreds of thousands of children could be impacted by this disruption of regular immunization services. This is a very serious threat. Early action is key."

.....  
.....

### **COVID-19 R&D – Vaccine Manufacturing Scaling**

#### **Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally**

:: Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment  
:: First in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19  
Apr 23, 2020

#### **Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna's Vaccine (mRNA-1273) Against Novel Coronavirus**

:: Collaboration goal to enable manufacturing of up to 1 billion doses per year  
:: Technology transfer expected to begin in June 2020  
:: First batches of mRNA-1273 expected to be manufactured at Lonza U.S. in July 2020  
:: Collaboration leverages Lonza's worldwide expertise in technology transfer and manufacturing  
May 01, 2020

.....  
.....

### **Featured Journal Content – JAMA Network: COVID-19 Update May 2, 2020**

#### **JAMA Research**

#### **Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs**

Rishi K. Wadhera, MD, MPP, MPhil; Priya Wadhera, MD, MS; Prakriti Gaba, MD; et al

#### **Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston**

Travis P. Baggett, MD, MPH; Harrison Keyes, MPAS, PA-C; Nora Sporn, MA, MPH; et al

**[Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment](#)**

Oren Feldman, MD; Michal Meir, MD; Danielle Shavit, BSc; et al

**[Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection](#)**

David Baud, MD, PhD; Gilbert Greub, MD, PhD; Guillaume Favre, MD; et al

***News & Insight***

**[Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19](#)**

Rita Rubin, MA

**[Public Health Measures and the Reproduction Number of SARS-CoV-2](#)**

Thomas V. Inglesby, MD

**[Twentieth-Century Lessons for a Modern Coronavirus Pandemic](#)**

Angel Desai, MD, MPH

***Opinion***

**[Moving Personal Protective Equipment Into the Community: Face Shields and Containment of COVID-19](#)**

Eli N. Perencevich, MD, MS; Daniel J. Diekema, MD, MS; Michael B. Edmond, MD, MPH, MPA

**[COVID-19 and Risks Posed to Personnel During Endotracheal Intubation](#)**

David N. Weissman, MD; Marie A. de Perio, MD; Lewis J. Radonovich Jr, MD

**[The Potential Effects of Coronavirus on National Health Expenditures](#)**

Sherry Glied, PhD; Helen Levy, PhD

**[The Business of Medicine in the Era of COVID-19](#)**

David M. Cutler, PhD; Sayeh Nikpay, PhD; Robert S. Huckman, PhD

***Humanities***

**[Lost Space](#)**

Renata Thronson, MD

**JAMA Health Forum**

***Opinion***

**[Hospital-at-Home to Support COVID-19 Surge—Time to Bring Down the Walls?](#)**

Shantanu Nundy, MD, MBA; Kavita K. Patel, MD, MSHS

**[COVID-19 Reveals Urgent Need to Strengthen the World Health Organization](#)**

Lawrence O. Gostin, JD

**[Data and Policy Solutions to Address Racial and Ethnic Disparities in the COVID-19 Pandemic](#)**

Utibe R. Essien, MD, MPH; Atheendar Venkataramani, MD, PhD

## **JAMA Internal Medicine**

### ***Research***

#### **[Internet Searches for Unproven COVID-19 Therapies in the United States](#)**

Michael Liu, AB; Theodore L. Caputi, MPH; Mark Dredze, PhD; et al

#### **[Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset](#)**

Hao-Yuan Cheng, MD, MSc; Shu-Wan Jian, DVM, MPH; Ding-Ping Liu, PhD; et al

### ***Opinion***

#### **[The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19—First, Do No Harm](#)**

Colette DeJong, MD; Robert M. Wachter, MD

#### **[COVID-19 in Prisons and Jails in the United States](#)**

Laura Hawks, MD; Steffie Woolhandler, MD, MPH; Danny McCormick, MD, MPH

#### **[Contact Tracing, Testing, and Control of COVID-19—Learning From Taiwan](#)**

Robert Steinbrook, MD

## **JAMA Cardiology**

### ***Research***

#### **[Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 \(COVID-19\)](#)**

Nicholas J. Mercuro, PharmD, BCIDP; Christina F. Yen, MD; David J. Shim, MD, PhD; et al

#### **[Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 \(COVID-19\) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit](#)**

Francis Bessière, MD, PhD; Hugo Roccia, MD; Antoine Delinière, MD; et al

### ***Opinion***

#### **[Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation](#)**

Robert O. Bonow, MD, MS; Adrian F. Hernandez, MD, MHS; Mintu Turakhia, MD, MAS  
JAMA Psychiatry

### ***Clinical Review & Education***

#### **[Mental Health in the Coronavirus Disease 2019 Emergency—The Italian Response](#)**

Giovanni de Girolamo, MD; Giancarlo Cerveri, MD; Massimo Clerici, MD; et al

## **JAMA Surgery**

### ***Opinion***

**Rapid Development of Resident-Led Procedural Response Teams to Support Patient Care During the Coronavirus Disease 2019 Epidemic: A Surgical Workforce Activation Team**

Barbara E. Coons, MD; Sophia F. Tam, MD; Shunpei Okochi, MD

**To Face Coronavirus Disease 2019, Surgeons Must Embrace Palliative Care**

Zara Cooper, MD, MSc; Rachelle E. Bernacki, MD, MS

**JAMA Dermatology**

***Clinical Review & Education***

**Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection**

Adrien Sanchez, MD; Pierre Sohier, MD, PhD; Sarah Benghanem, MD; et al

**Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection**

Borja Diaz-Guimaraens, MD; Miguel Dominguez-Santas, MD; Ana Suarez-Valle, MD; et al

***Opinion***

**How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic**

Lauren M. Madigan, MD; Robert G. Micheletti, MD; Kanade Shinkai, MD, PhD  
JAMA Otolaryngology–Head & Neck Surgery

**Leveraging COVID-19–Inspired Changes to Advance Otolaryngology—Here to Stay**

Samir S. Khariwala, MD, MS; Heather M. Weinreich, MD, MPH; Edward D. McCoul, MD, MPH; et al

***Research***

**Negative-Pressure Aerosol Cover for COVID-19 Tracheostomy**

J. Tyler Bertroche, MD; Patrik Pipkorn, MD, MSCI; Paul Zolkind, MD; et al

**Pediatric Microlaryngoscopy and Bronchoscopy in the COVID-19 Era**

Katherine Pollaers, MBBS, MSurg; Hayley Herbert, MBChB; Shyan Vijayasekaran, MBBS

**A Simple Technique for Droplet Control During Mastoid Surgery**

Jeffrey D. Carron, MD; Lauren S. Buck, MD; Claude F. Harbarger, MD; et al  
Opinion

.....  
.....

**EMERGENCIES**

**Coronavirus [COVID-19]**

*Public Health Emergency of International Concern (PHEIC)*

## **Statement on the third meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of coronavirus disease (COVID-19)**

1 May 2020 *Statement*

Geneva, Switzerland

*[Excerpts]*

The third meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding the coronavirus disease (COVID-19), took place on Thursday, 30 April 2020, from 12:00 to 17:45 Geneva time (CEST)...

The WHO Regional Emergency Directors and the Executive Director of the WHO Health Emergencies Programme (WHE) provided regional and the global situation overview. After ensuing discussion, the Committee unanimously agreed that the outbreak still constitutes a public health emergency of international concern (PHEIC) and offered advice to the Director-General.

**The Director-General declared that the outbreak of COVID-19 continues to constitute a PHEIC.** He accepted the advice of the Committee to WHO and issued the Committee's advice to States Parties as Temporary Recommendations under the IHR.

The Emergency Committee will be reconvened within three months or earlier, at the discretion of the Director-General. The Director-General thanked the Committee for its work...

.....

### ***Editor's Note:***

We certainly recognize the velocity of global developments in the COVID-19 pandemic. While we have concentrated the most current key reports just below, COVID-19 announcements, analysis and commentary will be found throughout this issue, in all sections.

Beyond the considerable continuing coverage in the global general media, the WHO's authoritative guidance is available here:

**:: Daily WHO situation reports** here: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>

**:: WHO Coronavirus disease (COVID-2019) daily press briefings** here: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings>

### **Situation report - 103** [WHO]

Novel Coronavirus (COVID-19)

2 May 2020

*[Excerpts]*

#### **Situation in numbers (by WHO Region)**

*Total (new cases in last 24 hours)*

<b>Globally</b>	3 267 184 cases (91 977)	229 971 deaths (5799)
<b>Africa</b>	27 973 cases (1310)	1013 deaths (40)
<b>Americas</b>	1 340 591 cases (48 674)	72 196 deaths (3109)
<b>E Mediterranean</b>	194 991 cases (6406)	7741 deaths (143)
<b>Europe</b>	1 492 024 cases (30 620)	140 586 deaths (2386)
<b>South-East Asia</b>	60 490 cases (3402)	2256 deaths (82)



## **Western Pacific**

150 403 cases (1565)

6166 deaths (39)

### **HIGHLIGHTS**

:: No new country/territory/area reported cases of COVID-19 in the past 24 hours.

:: WHO and the European Investment Bank yesterday signed a collaboration agreement to accelerate investment in health preparedness and primary healthcare in countries most vulnerable to the COVID-19 pandemic. The first phase will strengthen primary healthcare in ten African countries. The Director-General Dr. Tedros, in his regular media briefing yesterday said that, with the signing of the agreement, "We are deepening our relationship with the European Union". He also reminded all that the European Commission will host a pledging conference on 4 May to raise funds for investment in vaccine research.

.....

### **Ethics and COVID-19: resource allocation and priority-setting**

WHO Working Group on Ethics and COVID-19

20 April 2020 :: 5 pages

#### *Overview*

Governments, international agencies and health systems have an obligation to ensure, to the best of their ability, adequate provision of health care for all. However, this may not be possible during a pandemic, when health resources are likely to be limited. Setting priorities and rationing resources in this context means making tragic choices, but these tragic choices can be ethically justified. This is why we have ethics. This policy brief answers a number of questions about the ethics of setting priorities for the allocation of resources during times of scarcity. Such decisions may include access to hospitals, ventilators, vaccines and medicines. It is essential that policies and practices are ethically justified in such contexts. The document provides a high-level ethical framework that can be used to guide decision-making, and complements WHO's technical guidance.

.....

### **Emergencies**

#### **Ebola – DRC+**

*Public Health Emergency of International Concern (PHEIC)*

#### **Ebola Outbreak in DRC 90: 28 April 2020**

*[Excerpts]*

#### ***Situation Update***

From 20 to 26 April 2020, there have been no new confirmed cases of Ebola virus disease (EVD) reported in the Democratic Republic of the Congo. Since the resurgence of the outbreak on 10 April 2020, six confirmed cases have been reported, all from the Kasanga Health Area in Beni Health Zone.

#### ***...Conclusion***

The resurgence of EVD in Beni Health Zone highlights the importance of heightened vigilance for this disease in the face of significant challenges around community engagement, access to

affected areas, ongoing insecurity, and limited response capacity due to other local and global emergencies. New cases are expected among contacts of recent cases. It is essential to detect, isolate, test and treat new suspected cases as early as possible in order to improve outcome of cases and break the chain of transmission. Strong coordination and communication among partners, the Ministry of Health, local authorities and the communities are essential to address these challenges. In addition, stronger advocacy for survivors is essential, such as mitigating rumours and stigmatization of EVD survivors.

.....  
.....

## **Emergencies**

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

#### **Polio this week as of 28 April 2020**

:: The Twenty-fourth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the Director General on 26 March 2020 with committee members only attending via teleconference, supported by the WHO Secretariat. [Read](#) the statement from the meeting.

#### ***Summary of new viruses this week (AFP cases and ES positives):***

- :: **Afghanistan:** one WPV1 case and one WPV1 positive environmental sample
- :: **Pakistan:** six WPV1 positive environmental samples, two cVDPV2 cases and two cVDPV2 positive environmental samples
- :: **Cote d'Ivoire:** one cVDPV2 case and six cVDPV2 positive environmental sample

.....

#### **WHO Grade 3 Emergencies** [to 2 May 2020]

##### **Democratic Republic of the Congo**

:: Ebola Outbreak in DRC 90: 28 April 2020

*[See Ebola above for detail]*

Nigeria - *No new digest announcements identified*

Somalia - *No new digest announcements identified*

South Sudan - *No new digest announcements identified*

Syrian Arab Republic - *No new digest announcements identified*

Yemen - *No new digest announcements identified*

.....

#### **WHO Grade 2 Emergencies** [to 2 May 2020]

Angola - *No new digest announcements identified*

Afghanistan - *No new digest announcements identified*

Burkina Faso [in French] - *No new digest announcements identified*

Burundi - *No new digest announcements identified*

Cameroon - *No new digest announcements identified*  
Central African Republic - *No new digest announcements identified*  
Ethiopia - *No new digest announcements identified*  
Iran - *No new digest announcements identified*  
Iraq - *No new digest announcements identified*  
Libya - *No new digest announcements identified*  
Malawi - *No new digest announcements identified*  
Measles in Europe - *No new digest announcements identified*  
MERS-CoV - *No new digest announcements identified*  
Myanmar - *No new digest announcements identified*  
Niger - *No new digest announcements identified*  
occupied Palestinian territory - *No new digest announcements identified*  
Sudan - *No new digest announcements identified*  
Ukraine - *No new digest announcements identified*  
Zimbabwe - *No new digest announcements identified*

.....

#### **WHO Grade 1 Emergencies** [to 2 May 2020]

Chad - *No new digest announcements identified*  
Djibouti - *No new digest announcements identified*  
Kenya - *No new digest announcements identified*  
Mali - *No new digest announcements identified*  
Namibia - viral hepatitis - *No new digest announcements identified*  
Tanzania - *No new digest announcements identified*

.....

.....

#### **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

##### **Syrian Arab Republic**

:: Syrian Arab Republic: COVID-19 Update No. 08 - 2 May 2020  
:: Syrian Arab Republic: Whole of Syria COVID-19 Response Update No.01 (As of 29 April 2020)

##### **Yemen**

:: 30 April 2020 Yemen: Flash Floods Flash Update No. 3 (As of 30 April 2020)

.....

#### **UN OCHA – Corporate Emergencies**

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

##### **CYCLONE IDAI and Kenneth**

:: 29 April 2020 Zimbabwe Situation Report, 29 Apr 2020

:: EBOLA OUTBREAK IN THE DRC - *No new digest announcements identified*

.....  
.....

## **WHO & Regional Offices** [to 2 May 2020]

1 May 2020 *Statement*

**[Statement on the third meeting of the International Health Regulations \(2005\) Emergency Committee regarding the outbreak of coronavirus disease \(COVID-19\)](#)**

1 May 2020 *News release*

**[Billions worldwide living with herpes](#)**

1 May 2020 *News release*

**[WHO and European Investment Bank strengthen efforts to combat COVID-19 and build resilient health systems to face future pandemics](#)**

:: WHO and the European Investment Bank enhance cooperation to support countries in addressing the health impact of COVID-19

:: **The first phase will address urgent needs and strengthen primary health care in ten African countries**

:: Enhanced WHO-EIB partnership will scale up financing to assure the chain of essential supplies, including personal protective equipment, diagnostics and clinical management

:: New initiative will accelerate investment in health preparedness and primary health care with a focus on health work force, infrastructure, and water, sanitation and hygiene

:: The initiative involves measures to address the growing threat of antimicrobial resistance

27 April 2020 *Statement*

**[WHO Timeline - COVID-19](#)**

.....

**[Weekly Epidemiological Record, 1 May 2020, vol. 95, 18 \(pp. 173–184\)](#)**

Progress towards maternal and neonatal tetanus elimination – worldwide, 2000–2018

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

*No new digest content identified.*

### **WHO Region of the Americas PAHO**

*No new digest content identified.*

### **WHO South-East Asia Region SEARO**

:: 29 April 2020 *News release*

WHO convenes manufacturers, regulatory authorities meet on COVID-19 vaccines

## **WHO European Region EURO**

- :: COVID-19 pandemic remains public health emergency of international concern 02-05-2020
- :: WHO/Europe COVID-19 mission on route to Tajikistan at Government's request 01-05-2020
- :: Vital health protection steps must be continued during COVID-19 30-04-2020
- :: Through transparent knowledge-sharing, tailored support on the ground, and steadfast solidarity we will beat COVID-19 29-04-2020
- :: COVID-19 exposes the critical importance of patient rehabilitation 28-04-2020

## **WHO Eastern Mediterranean Region EMRO**

- :: Statement by WHO's Regional Director Dr Ahmed Al-Mandhari on our collective fight against COVID-19 28 April 2020

## **WHO Western Pacific Region**

*No new digest content identified.*

.....  
.....

## **CDC/ACIP [to 2 May 2020]**

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases*

## **CDC launches national viral genomics consortium to better map SARS-CoV-2 transmission**

*Rapid release of open coronavirus sequence data will help guide COVID-19 public health response, drive innovation and discovery, and advance understanding of this and future pandemics*

Friday, May 1, 2020

CDC has kicked off the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium, which will greatly expand the use of whole genome sequencing (WGS) of the COVID-19 virus.

This national network of sequencing laboratories will speed the release of SARS-CoV-2 sequence data into the public domain.

SPHERES will provide consistent, real-time sequence data to the public health response teams investigating cases and clusters of COVID-19 across the country. It will help them better understand how the virus is spreading, both nationally and in their local communities. Better data, in turn, will help public health officials interrupt chains of transmission, prevent new cases of illness, and protect and save lives...

## **MMWR News Synopsis Friday, May 1, 2020**

- :: Progress Toward Maternal and Neonatal Tetanus Elimination — Worldwide, 2000–2018
- :: Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters — Four U.S. Cities, March 27–April 15, 2020 (Early Release April 22, 2020)
- :: COVID-19 Outbreak Among Three Affiliated Homeless Service Sites — King County, Washington, 2020 (Early Release April 22, 2020)

.....

**Africa CDC** [to 2 May 2020]

<http://www.africacdc.org/>

*Press Releases*

**Outbreak Brief 15: COVID-19 Pandemic – 28 April 2020**

28 April 2020

.....

**China CDC**

<http://www.chinacdc.cn/en/>

*No new digest content identified.*

**National Health Commission of the People's Republic of China**

<http://en.nhc.gov.cn/>

*News*

**May 2: Daily briefing on novel coronavirus cases in China**

On May 1, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 1 new case of confirmed infections, 2 new cases of suspected infections, and no deaths.

**Xi, two leaders discuss mankind's shared future**

2020-05-02

China stands ready to work with the international community, including the Czech Republic and Peru, to jointly respond to the COVID-19 pandemic, and it supports international coordination on macroeconomic policies to offset the impact of the epidemic on the world economy, President Xi Jinping said on April 30.

Xi made the remarks in separate telephone conversations with Czech President Milos Zeman and Peruvian President Martin Vizcarra.

**WHO reiterates novel coronavirus is "natural in origin"**

2020-05-02

.....

.....

**Announcements**

**Paul G. Allen Frontiers Group** [to 2 May 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

**Scientists are working on a face mask that detects coronavirus**

April 23, 2020

Q&A with James Collins, Ph.D., a bioengineer who is developing a diagnostic face mask that signals if the wearer is infected with COVID-19

**BMGF - Gates Foundation** [to 2 May 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>  
*Website under maintenance at inquiry.*

**Bill & Melinda Gates Medical Research Institute** [to 2 May 2020]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

**[InVivo Profiles Bill & Melinda Gates Medical Research Institute](#)**

**CARB-X** [to 2 May 2020]

<https://carb-x.org/>

*CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.  
No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 2 May 2020]

<http://cepi.net/>

*Latest News*

**[CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian Subsidiary](#)**

27 Apr 2020

**[CEPI establishes Representative Office in Shanghai, China](#)**

27 Apr 20

**Clinton Health Access Initiative, Inc. (CHAI)** [to 2 May 2020]

<https://clintonhealthaccess.org/>

*News & Press Releases*

April 28, 2020

**[Unitaid and CHAI announce agreement with Omega Diagnostics to increase access to new, portable CD4 testing device for people living with HIV in over 130 low- and middle-income countries](#)**

Agreement with Omega Diagnostics will help deliver same-day CD4 testing for people living with HIV in over 130 low- and middle-income countries at just US\$3.98 per test.

**EDCTP** [to 2 May 2020]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against*

*HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*  
*Latest news*  
*No new digest content identified.*

**Emory Vaccine Center** [to 2 May 2020]

<http://www.vaccines.emory.edu/>

[Undated]

**EVC RESONDS TO COVID-19**

EVC COVID-19 RESEARCH UPDATE

**European Medicines Agency** [to 2 May 2020]

<http://www.ema.europa.eu/ema/>

*News & Press Releases •*

**Press release: EMA starts rolling review of remdesivir for COVID-19**

Last updated: 30/04/2020

**News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020**

CHMP, Last updated: 30/04/2020

**Press release: EU actions to support availability of medicines during COVID-19 pandemic – update #4**

Last updated: 30/04/2020

**News: International regulators pledge collective support to combat COVID-19 pandemic**

Last updated: 28/04/2020

**European Vaccine Initiative** [to 2 May 2020]

<http://www.euvaccine.eu/news-events>

*Latest News*

*No new digest content identified.*

**FDA** [to 2 May 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements*

**May 1, 2020 - Coronavirus (COVID-19) Update: Daily Roundup May 1, 2020**

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

**:: Today, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug remdesivir.** The EUAExternal Link Disclaimer allows for remdesivir to be distributed in the :: U.S. and administered by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children



hospitalized with severe disease. Severe disease is defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator. Based on evaluation of the emergency use authorization criteria and the scientific evidence available, it was determined that it is reasonable to believe that remdesivir may be effective in treating COVID-19, and that, given there are no adequate, approved, or available alternative treatments, the known and potential benefits to treat this serious or life-threatening virus currently outweigh the known and potential risks of the drug's use. For more information see: [news release](#), [Health Care Provider Fact Sheet](#) and [Patient Fact Sheet](#).

**:: Today, the FDA updated its guidance on convalescent plasma and associated [web page](#).** The updated guidance provides clarification for investigators on how to submit investigational applications for COVID-19 convalescent plasma. In addition, the guidance includes updated information regarding potential donors. Previously, the FDA's guidance noted that to qualify, individuals should have complete resolution of symptoms for 28 days or resolution for 14 and a negative diagnostic test. The revised guidance recommends that individuals have complete resolution of symptoms for at least 14 days prior to donation. A negative lab test for COVID-19 disease is not necessary to qualify for donation. The revised guidance also clarifies that FDA does not recommend storing a retention sample from the convalescent plasma donation for single patient emergency INDs...

### **[May 1, 2020 - Coronavirus \(COVID-19\) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment](#)**

Today, the U.S. Food and Drug Administration [issued an emergency use authorization](#) for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in a clinical trial to shorten the time to recovery in some patients.

**"FDA's emergency authorization of remdesivir, two days after the National Institutes of Health's clinical trial showed promising results, is a significant step forward in battling COVID-19** and another example of the Trump Administration moving as quickly as possible to use science to save lives," said HHS Secretary Alex Azar. "NIH, FDA, and scientists across America and around the world have worked tirelessly with patients to get us this new potential treatment for COVID-19. The seamless cooperation between government and private industry under the President's all-of-America approach to COVID-19 is getting treatment options to patients in record time."

The emergency use authorization allows for remdesivir to be distributed in the U.S. and administered intravenously by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator...

**Fondation Merieux** [to 2 May 2020]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 2 May 2020]

<https://www.gavi.org/>

*Top Stories*

1 May 2020

**28 April 2020: Overview of the COVID-19 situation in Gavi-supported countries and Gavi's response**

1 May 2020

**Keeping routine immunisation going during COVID-19 in Indonesia**

30 April 2020

**World Immunization Week: Eradicating cervical cancer through HPV vaccination**

**GHIT Fund** [to 2 May 2020]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that  
No new digest content identified.*

**Global Fund** [to 2 May 2020]

<https://www.theglobalfund.org/en/news/>

*Updates*

**Ethics Resources for Country Coordinating Mechanisms**

30 April 2020

Ethical, transparent and responsible decision-making by Country Coordinating Mechanisms is key for the success of programs in countries – and advancing the fight against HIV, tuberculosis and malaria worldwide.

To support Country Coordinating Mechanisms in following the highest standards of ethics and integrity, the Global Fund has published new resources:

Translations of the Code of Ethical Conduct for Country Coordinating Mechanism Members

:: An e-learning course introducing the Code of Ethical Conduct

:: Guidelines for ethics focal points and ethics committees

To access these resources and for more information, see the Country Coordinating Mechanism

[Ethics](#) page.

**Hilleman Laboratories** [to 2 May 2020]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 2 May 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

*Press Releases*

**Global COVID Lab Meeting Will Bring Together the Worldwide Scientific Community to Accelerate Development of Vaccines and Immunotherapies**

Apr 30, 2020

New York City (April 23, 2020). The Global COVID Lab Meeting will connect the worldwide scientific community working to develop vaccines and immunotherapies to end the COVID-19 pandemic. The Human Vaccines Project is starting this bi-weekly webinar to feature leading scientists from across the globe presenting their latest data, with ample time allowed for questions and discussion.

"The engines of science are the weekly or bi-weekly lab meetings held across the globe by individual laboratory directors, enabling faculty, post-docs and graduate students to present their latest findings and catalyze new ideas," says Wayne C. Koff, president and CEO of the Human Vaccines Project. "The urgency of the pandemic, coupled with technological advances of distance learning, now enables us to bring the global scientific community together to accelerate the development of vaccines and immunotherapies for prevention and control of COVID-19. The Global COVID Lab Meeting will provide researchers with a neutral forum to share their findings and innovative ideas with scientists from across the world on a regular basis, thereby increasing the probability for identifying solutions towards ending the COVID-19 pandemic."

The webinar will be held every first and third Thursday of the month at 10 am EST. The first session is on May 7th. Dr. James E. Crowe Jr., Director of the Vanderbilt Vaccine Center, will talk about his studies on identification and development of human monoclonal antibodies for SARS-CoV-2 – a treatment that could provide immediate immunity to first responders. Dr. Crowe's lab is one of the leading groups globally working on antibody identification and is targeting starting clinical studies early this summer for SARS-CoV-2 therapeutics. [You can register for the webinar here.](#)

#### **IAVI** [to 2 May 2020]

<https://www.iavi.org/newsroom>

*Press Releases*

*No new digest content identified.*

#### **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

#### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

#### **IFFIm**

<http://www.iffim.org/>

*Press Releases*

*No new digest content identified.*

**IFRC** [to 2 May 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*No new digest content identified.*

**IVAC** [to 2 May 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates*

**Vaccination Services Must Continue Even as We Fight COVID-19**

April 2020

By Dr. Chizoba Wonodi, Immunization Technical Lead, USAID's MOMENTUM 2A: Global Technical Leadership and Targeted Technical Assistance

Nigeria, like all other countries in the world, is grappling with the devastating public health, social, and economic fallouts of the COVID-19 pandemic. As of April 27, 2020, Nigeria has 1273 confirmed cases, a dramatic increase since February [...]

**IVI** [to 2 May 2020]

<http://www.ivi.int/>

*Selected IVI News & Announcements*

**INOVO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference**

*:: INO-4700 (GLS-5300) DNA vaccine demonstrates 100% binding and 92% neutralizing antibody responses against MERS-CoV*

*:: INO-4800 DNA vaccine for COVID-19 currently in Phase 1 trial utilizes identical strategy targeting Spike protein and CELLECTRA intradermal delivery*

April 28, 2020

**JEE Alliance** [to 2 May 2020]

<https://www.jeealliance.org/>

*Selected News and Events*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 2 May 2020]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Vaccination*

**Overcoming barriers so vaccines can save lives**

Project Update 29 Apr 2020

*Coronavirus COVID-19 pandemic*

**Overwhelming, lonely, stressful – life in a COVID-19 unit in Geneva**

Voices from the Field 27 Apr 2020

**National Vaccine Program Office - U.S. HHS** [to 2 May 2020]

<https://www.hhs.gov/vaccines/about/index.html>

*NVAC 2020 Meetings*

[June 9-10, 2020 NVAC Meeting](#)

[September 23-24, 2020 Meeting \(Virtual\)](#)

**NIH** [to 2 May 2020]

<http://www.nih.gov/news-events/news-releases>

*Selected News Releases*

[NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19](#)

April 29, 2020 — Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo.

[NIH mobilizes national innovation initiative for COVID-19 diagnostics](#)

April 29, 2020 — Initiative aims to speed delivery of accurate, easy-to-use, scalable tests to all Americans.

**PATH** [to 2 May 2020]

<https://www.path.org/media-center/>

*Selected Announcements*

April 24, 2020

[PATH establishes Representative Office in Shanghai, China](#)

Registration will enable PATH to implement health projects directly with partners

[PATH partners with Ukraine to develop a national response to COVID-19](#)

Seattle, WA, April 24, 2020 – PATH is partnering with the Ukraine government to develop and implement a comprehensive national response to COVID-19. PATH'S country office program will use the expertise acquired from leading infectious disease surveillance, pandemic flue emergency preparedness, and tuberculosis control in Ukraine since 1994 to address four important areas of the national response...

**Sabin Vaccine Institute** [to 2 May 2020]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 2 May 2020]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

1 May 2020

[Paying tribute to care workers during an online Labour Day event](#)

1 May 2020

**"The concern did not just come from the community, but also the health workers"**

29 April 2020

**"We must ensure that HIV treatment adherence is not compromised"—keeping people in Pakistan on HIV treatment**

28 April 2020

**"I've saved lives on the frontline of the COVID-19 pandemic in China"**

28 April 2020

**Women are more likely to be on HIV treatment**

**UNICEF** [to 2 May 2020]

<https://www.unicef.org/media/press-releases>

*Press release*

**Geneva Palais briefing note on the impact of COVID-19 mitigation measures on vaccine supply and logistics**

01/05/2020

*[See COVID-19 above for detail]*

*Statement*

**COVID-19 & Immigration Detention: What Can Governments and Other Stakeholders Do?**

Statement by the United Nations Network on Migration

29/04/2020

*Press release*

**Over 5 million children face threat of cholera and acute water diarrhea in the midst of COVID-19 as Yemen gets heavy rains**

29/04/2020

*Press release*

**Disruption of childhood vaccination in South Asia poses an urgent threat to children's health – UNICEF**

4.5 million of South Asia's children miss out on routine immunization, even before COVID-19

28/04/2020

*[See COVID-19 above for detail]*

*Press release*

**COVID-19: Gavi and UNICEF to secure equipment and diagnostics for lower-income countries**

28/04/2020

**Unitaid** [to 2 May 2020]

<https://unitaid.org/>

*Featured News*

27 April 2020

**[Unitaid congratulates Ellen 't Hoen on national honour recognising her efforts on access and equity](#)**

Geneva — Unitaid congratulates Ellen 't Hoen on the announcement that H.M. King Alexander of the Netherlands has conferred on her the title of 'Officier in de Orde van Oranje-Nassau', in recognition of her important contribution on global health and access to medicines at the international level.

Amongst her many achievements, Ellen 't Hoen was instrumental in setting up the Medicines Patent Pool ten years ago in 2010, which Unitaid has funded since its creation. She also was its first Executive Director...

**Vaccination Acceptance Research Network (VARN)** [to 2 May 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 2 May 2020]

<http://www.vaccineconfidence.org/>

*Latest News & Archive*

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 2 May 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*No new digest content identified.*

**Wellcome Trust** [to 2 May 2020]

<https://wellcome.ac.uk/news>

*Opinion* | 29 April 2020

**[COVID-19: how researchers around the world are racing to understand the virus and prevent future outbreaks](#)**

by Josie Golding

*News* | 27 April 2020

**[The future of vaccines: three innovations from around the world](#)**

World Immunisation Week is an opportunity to celebrate some of the most cutting-edge vaccination projects and technologies from around the world, which have the potential to improve health for millions of people.

**The Wistar Institute** [to 2 May 2020]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*Press Release* May. 1, 2020

**The Wistar Institute Appoints Bin Tian, Ph.D., as Professor in the Cancer Center and Co-director of the Center for Systems & Computational Biology**

PHILADELPHIA — (May, 1, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of molecular systems biologist Bin Tian, Ph.D., as professor in the Cancer Center.

*Press Release* Apr. 30, 2020

**The Wistar Institute Appoints Virology Expert Italo Tempera, Ph.D., as Associate Professor in Its Cancer Center**

PHILADELPHIA — (April 30, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Italo Tempera, Ph.D., as associate professor in the Gene Expression & Regulation Program of The Wistar Institute Cancer Center.

*Press Release* Apr. 29, 2020

**The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar's Rubella Vaccine Globally**

The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines

**WFPHA: World Federation of Public Health Associations** [to 2 May 2020]

<https://www.wfpha.org/>

*Latest News*

**Open Letter to The United Nations: Call for The Establishment of a Multi-sector "Global Health Equity Task Force" to Confront The Impact of COVID-19 Pandemic**

Monday, 27 April 2020

Global Health Inequity is a fact. The present crisis renders visible these inequities. The World Federation of Public Health Associations (WFPHA) has signed an open letter to the United Nations proposing that the UN Secretary General provide the necessary support to the World Health Organization (WHO), by creating a multi-sector "Global Health Equity Task Force" to confront the impact of the COVID-19 pandemic in its full health, socio-demographic and economic dimensions.

As the unique international non-governmental body representing the interests of the global public health community through national and regional public health associations and associated organizations, WFPHA is concerned about the impact of the COVID-19 pandemic among already vulnerable and marginalized populations worldwide. Disadvantaged and marginalized populations are more at risk to become infected. When infected, marginalized people are more likely to evolve to severe cases as they suffer disproportionately higher rates of chronic diseases, obesity and malnutrition.

The "Global Health Equity Task Force", housed within WHO, would be charged with taking the necessary steps to exert needed global leadership for a comprehensive, equity-focused response to the pandemic, guided by the ethical principles of justice, beneficence and nonmaleficence and the Universal Declaration of Human Rights. It would encourage international cooperation towards fair allocation of resources to all countries according to need.



Full Letter with List of Institutions is Available [Here](#).  
List of Individual Signing the Letter is Available [Here](#).

**World Organisation for Animal Health (OIE)** [to 2 May 2020]

<https://www.oie.int/en/for-the-media/press-releases/2020/>

*Press Releases*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 2 May 2020]

<https://alliancerm.org/press-releases/>

*Press Releases*

*No new digest content identified.*

**BIO** [to 2 May 2020]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 2 May 2020]

<http://www.dcvmn.org/>

*News*

**[DCVMN joined Global leaders call for a new collaboration to accelerate equitable access to Covid-19 Health technologies](#)**

Geneva, 24th April 2020 - The COVID-19 pandemic requires a strong united front to turn the tide of this global public health burden. Recognizing the April 20th United Nations General Assembly resolution [[1](#)], calling for rapid development, scale-up, manufacturing and supply of vaccines to confront the pandemic, the Developing Countries Vaccine Manufacturers Network (DCVMN) stands ready to fully collaborate with the Access to COVID Tools (ACT) Accelerator initiative, launched on 24th April 2020...

**IFPMA** [to 2 May 2020]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

**[Global Pharma update on unprecedented efforts to collaborate in speeding up the search for safe](#)**

30 April 2020

**PhRMA** [to 2 May 2020]

<http://www.phrma.org/>

*Selected Press Releases, Statements*

**[The continued imperative to protect U.S. innovation worldwide](#)**

Chris Moore | April 29, 2020

The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are collaborating with others and working around the clock to research and develop vaccines and treatments to beat the virus.

The 2020 Special 301 Report released today by the Office of the United States Trade Representative (USTR) highlights just how essential open markets and effective intellectual property protections and enforcement are to meeting today's challenges and to delivering tomorrow's new treatments and cures. The report confirms the U.S. government's strong commitment to defend and promote fair market access for American inventions, including biopharmaceuticals, in countries around the world.

Thanks to its domestic intellectual property and market-based policy environment, the United States leads the world in the research and development of new medicines. With the right policies in place, the new treatments and cures pioneered here can continue to benefit patients everywhere. There are notable examples from the 2020 Special 301 Report of how USTR is defending American innovators:

- :: Ensuring transparency and fairness of pharmaceutical pricing and reimbursement policies in Canada, Japan and South Korea so trading partners appropriately recognize the value of innovative medicines and contribute their fair share to research and development of new treatments and cures.

- :: Combating the negative impact of compulsory licensing actions in Asia, the Middle East, Latin America and other regions.

- :: Condemning weak intellectual property protection and other policies in Argentina, India, Malaysia, and enhancing engagement with Saudi Arabia by conducting an out-of-cycle review to resolve longstanding concerns...

### **Guest Post: Preserving clinical research sites during the coronavirus pandemic**

April 29, 2020

Jim Kremidas, executive director of the Association of Clinical Research Professionals

\*

\*

\*

\*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **American Journal of Infection Control**

May 2020 Volume 48, Issue 5, p471-590

<http://www.ajicjournal.org/current>

***The Importance of Hand Hygiene in the Current Healthcare Environment***

[New issue; No digest content identified]

**American Journal of Preventive Medicine**

May 2020 Volume 58, Issue 5, p613-756

<http://www.ajpmonline.org/current>

*Current Issues*

**Reducing Health Disparities Through Prevention: Role of the U.S. Preventive Services Task Force**

Matthew J. O'Brien, Kate A. Kirley, Ronald T. Ackermann

p724–727

Published online: February 23, 2020

**American Journal of Public Health**

May 2020 110(5)

<http://ajph.aphapublications.org/toc/ajph/current>

*VACCINES*

**Vaccine Communication as Weaponized Identity Politics**

Media, Immunization/Vaccines, Social Science

David A. Broniatowski, Sandra C. Quinn, Mark Dredze and Amelia M. Jamison

110(5), pp. 617–618

**Russian Twitter Accounts and the Partisan Polarization of Vaccine Discourse, 2015–2017**

Global Health, Media, Immunization/Vaccines, Social Science

Dror Walter, Yotam Ophir and Kathleen Hall Jamieson

110(5), pp. 718–724

*CORONAVIRUS*

**Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters**

Global Health, Government, Infections, Public Health Practice, Other Infections

Nathaniel Smith and Michael Fraser

110(5), pp. 648–649

*FLU SHOT*

**Influenza Vaccination Coverage of Health Care Personnel in Los Angeles County Hospitals, 2016–2017**

Health Care Facilities/Services, Immunization/Vaccines, Infections, Prevention, Public Health Practice, Public Health Workers

Talar Kamali, Chelsea Foo, Kelsey OYong and Dawn Terashita

110(5), pp. 693–695

**American Journal of Tropical Medicine and Hygiene**

Volume 102, Issue 4, April 2020

<http://www.ajtmh.org/content/journals/14761645/102/4>  
[Reviewed earlier]

### **Annals of Internal Medicine**

21 April 2020 Vol: 172, Issue 8  
<http://annals.org/aim/issue>  
[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 282 May 2020  
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/282/suppl/C>  
[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>  
(Accessed 2 May 2020)  
[No new digest content identified]

### **BMJ Global Health**

April 2020 - Volume 5 - 4  
<https://gh.bmj.com/content/5/4>  
[Reviewed earlier]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>  
(Accessed 2 May 2020)

#### **[Assessment of a novel scanner-supported system for processing of child health and immunization data in Uganda](#)**

*Electronic data capturing has the potential to improve data quality and user-friendliness compared to manually processed, paper-based documentation systems. The MyChild system uses an innovative approach to pr...*

Authors: Annika Åijö, Ina Schäffner, Peter Waiswa, Rornald Muhumuza Kananura, Mesfin Kassaye Tessma and Claudia Hanson

Citation: BMC Health Services Research 2020 20:367

Content type: Research article

Published on: 29 April 2020

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>  
(Accessed 2 May 2020)  
[No new digest content identified]

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 2 May 2020)

### **COVID-19: where is the national ethical guidance?**

Authors: Richard Huxtable

Content type: Editorial

1 May 2020

#### *Introduction*

The COVID-19 pandemic poses numerous – and substantial – ethical challenges to health and healthcare. Debate continues about whether there is adequate protective equipment, testing and monitoring, and about when a vaccine might become available and social restrictions might be lifted. The thorny dilemmas posed by triage and resource allocation also attract considerable attention, particularly access to intensive care resources, should demand outstrip supply.

But the “COVID fog” clouds more than the intensive care unit [1]. The provision and uptake of non-COVID related treatment is declining, due to the de-prioritisation of some services and interventions, alongside non-COVID patients’ fears of contracting the virus; difficult conversations are being held in suboptimal circumstances; and final farewells and death rituals have been disrupted. Healthcare personnel, meanwhile, are facing moral distress and, for some, difficulties arising from undertaking new roles in unfamiliar settings.

Whilst patients and the public require support, health and social care professionals also need guidance to help navigate the ethical challenges. A pandemic (by definition) respects no geographical boundaries, so co-ordinated international efforts will be important [2]. But guidance will also be needed to inform decision-making in health and social care within and throughout countries...

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 2 May 2020)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 2 May 2020)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 2 May 2020)

### **Barriers and facilitators to dissemination and adoption of precision medicine among Hispanics/Latinos**

*With the rapid advances in gene technologies in recent years, the potential benefits of precision medicine (PM) may spread unevenly to disadvantaged populations, such as Hispanics/Latinos. The objective of this study was to explore patient-level barriers and facilitators to dissemination and adoption of PM among Hispanics/Latinos, including knowledge and awareness.*

Authors: Juan R. Canedo, Consuelo H. Wilkins, Nicole Senft, Araceli Romero, Kemberlee Bonnet and David Schlundt  
Citation: BMC Public Health 2020 20:603  
Content type: Research article  
Published on: 1 May 2020

**The social value of investing in public health across the life course: a systematic scoping review**

*Making the case for investing in public health by illustrating the social, economic and environmental value of public health interventions is imperative. Economic methodologies to help capture the social value...*

Authors: Kathryn Ashton, Peter Schröder-Bäck, Timo Clemens, Mariana Dyakova, Anna Stielke and Mark A. Bellis  
Citation: BMC Public Health 2020 20:597  
Content type: Research article  
Published on: 1 May 2020

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 2 May 2020)

[No new digest content identified]

**BMJ Open**

April 2020 - Volume 10 - 4

<https://bmjopen.bmj.com/content/10/4?current-issue=y>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 98, Number 5, May 2020

<https://www.who.int/bulletin/volumes/98/5/en/>

*EDITORIALS*

**Simulation of the effects of COVID-19 testing rates on hospitalizations**

— Bernardo Sousa-Pinto, João Almeida Fonseca, Bruno Oliveira, Ricardo Cruz-Correia, Pedro Pereira Rodrigues, Altamiro Costa-Pereira & Francisco Nuno Rocha-Gonçalves  
<http://dx.doi.org/10.2471/BLT.20.258186>

*RESEARCH*

**Evidence of behaviour change during an Ebola virus disease outbreak, Sierra Leone**

— F Jalloh, Paul Sengh, Rebecca E Bunnell, Mohammad B Jalloh, Roeland Monasch, Wenshu Li, Jonathan Mermin, Nickolas DeLuca, Vance Brown, Sophia A Nur, Euna M August, Ray L Ransom, Apophia Namageyo-Funa, Sara A Clements, Meredith Dyson, Kathy Hageman, Samuel Abu Pratt, Azizeh Nuriddin, Dianna D Carroll, Nicole Hawk, Craig Manning, Sara Hersey, Barbara J Marston, Peter H Kilmarx, Lansana Conteh, Anna Mia Ekström, Zangin Zeebari, John T Redd, Helena Nordenstedt & Oliver Morgan  
<http://dx.doi.org/10.2471/BLT.19.245803>

**Child Care, Health and Development**

Volume 46, Issue 3 Pages: 249-396 May 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

**Clinical Therapeutics**

March 2020 Volume 42, Issue 3, p379-550, e33-e64

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

**Clinical Trials**

Volume 17 Issue 1, February 2020

<https://journals.sagepub.com/toc/ctja/17/1>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 2 May 2020]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 90 March 2020

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/90/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 3, Issue 2 / April 2020

<https://www.liebertpub.com/toc/crispr/3/2>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 8, Issue 1, March 2020

<https://link.springer.com/journal/40142/8/1>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

April 2020 - Volume 33 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Developing World Bioethics**

Volume 20, Issue 1 Pages: 1-60 March 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 30, Issue 2, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 14 - Issue 1 - February 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 44, Issue 2 Pages: 233-432 April 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

**EMBO Reports**

Volume 21 Issue 4 3 April 2020

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

**Emerging Infectious Diseases**

Volume 26, Number 4—April 2020

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

**Epidemics**

Volume 30 March 2020

<https://www.sciencedirect.com/journal/epidemics/vol/30/suppl/C>

[Reviewed earlier]

**Epidemiology and Infection**

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>



[Reviewed earlier]

### **Ethics & Human Research**

Volume 42, Issue 2 Pages: 1-33 March–April 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Incidental Findings :: Data Sharing N-of-1 Trials :: Deception***

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 30, Issue 2, April 2020

<https://academic.oup.com/eurpub/issue/30/2>

*Editorials*

**[How can evidence and strategies influence policies?](#)**

Pekka Puska

European Journal of Public Health, Volume 30, Issue 2, April 2020, Page 205,

<https://doi.org/10.1093/eurpub/ckz226>

*Vaccination*

**[The Dutch influenza vaccination policy and medication use, outpatient visits, hospitalization and mortality at age 65](#)**

Tom Van Ourti, Nicolas Bouckaert

European Journal of Public Health, Volume 30, Issue 2, April 2020, Pages 275–280,

<https://doi.org/10.1093/eurpub/ckaa016>

**[Rotavirus vaccination impact, Ireland, implications for vaccine confidence and screening](#)**

Heather E Burns, Abigail M Collins, Una B Fallon, Paul V Marsden, Caitlin M Ni Shuilleabhain

European Journal of Public Health, Volume 30, Issue 2, April 2020, Pages 281–285,

<https://doi.org/10.1093/eurpub/ckz238>

**[Knowledge and beliefs on vaccines among a sample of Italian pregnant women: results from the NAVIDAD study](#)**

Fabrizio Bert, Elena Olivero, Paola Rossello, Maria R Gualano, Silvana Castaldi ...

European Journal of Public Health, Volume 30, Issue 2, April 2020, Pages 286–292,

<https://doi.org/10.1093/eurpub/ckz209>

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 2 May 2020]

*Research Article metrics AWAITING PEER REVIEW*

**[Tetanus vaccine coverage in recommended and more than recommended doses among mothers in a West Cameroon health district: a cross sectional study](#)**

*[version 1; peer review: awaiting peer review]*

Igor Nguemouo Nguengang, Martin Nguestop, Linda Evans Eba Ze, Trevor Anyambod Mboh, Dominique Majoric Omokolo, Ruth Noutakdie Fossi, Etienne Guenou, Jerome Ateudjieu

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[No new digest content identified]

### **Global Health Action**

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 8, No. 1 March 30, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Public Health**

Volume 15, 2020 Issue 5

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 2 May 2020]

#### **[Understanding China's growing involvement in global health and managing processes of change](#)**

Authors: Lewis Husain and Gerald Bloom

Content type: Review

1 May 2020

### **Health Affairs**

Vol. 39, No. 4 April 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

#### ***Integrating Social Services & Health***

[Reviewed earlier]

### **Health and Human Rights**

<https://www.hhrjournal.org>

[Accessed 2 May 2020]

*Viewpoints*

### **Upholding Rights Under COVID-19: The Respectful Maternity Care Charter**

R. Rima Jolivet, Charlotte E Warren, Pooja Sripad, Elena Ateva, Jewel Gausman, Kate Mitchell, Hagar Palgi Hacker, Emma Sacks, and Ana Langer, 1 May 2020

*[Excerpt]*

...Human rights are indivisible and universal. Rights frameworks provide a firm legal and ethical foundation to guide policy and practice in a pandemic. Solutions that uphold fundamental human rights and best clinical practices, including infection control, contribute to stronger health and human rights outcomes overall. The Respectful Maternity Care (RMC) Charter, published in 2011 and updated in 2019, articulates 10 fundamental rights of childbearing women and newborns based on widely accepted human rights instruments, and provides a framework for high-quality care that supports and upholds the dignity of all parties...

### **Contact Tracing Apps: Extra Risks for Women and Marginalized Groups**

Sara L.M. Davis, 29 April 2020

*[Excerpt]*

...Groups that have historically experienced discrimination, stigma, and abuse may be exposed to greater risk of persecution as data on coronavirus transmission circulates and is discussed in the public sphere. Much of the public debate over digital contact tracing apps, rapidly unfolding in Europe, has so far focused on individual privacy, and on whether it can be protected with technical solutions.<sup>[1]</sup> These are important questions, but it sidesteps the harder problems linked to widespread stigma and blame. In some countries, states now impose criminal sanctions on transmission of the coronavirus, though UNAIDS warns, based on experience in the HIV epidemic, that criminal sanctions will undermine, not help the response.<sup>[2]</sup> Even anonymized data raises the risk of persecution once it circulates in a climate of fear and stigma...

### **Health Economics, Policy and Law**

Volume 15 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 35, Issue 3, April 2020

<https://academic.oup.com/heapol/issue/35/3>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 2 May 2020]

[No new digest content identified]

### **Human Gene Therapy**

Volume 31, Issue 7-8 / April 2020

<https://www.liebertpub.com/toc/hum/31/7-8>

[Reviewed earlier]

### **Humanitarian Exchange Magazine**

Number 77, March 2020

<https://odihpn.org/magazine/the-crisis-in-yemen/>

#### ***Responding to Ebola in the Democratic Republic of Congo***

by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world's second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA's flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Badjonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelicia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 16, Issue 4, 2020

<http://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 2 May 2020]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 2 May 2020]

[No new digest content identified]

### **International Health**

Volume 12, Issue 2, March 2020

<https://academic.oup.com/inthealth/issue/12/2>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol 7, No 5 (2020) May 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/62>

*Original Research Articles*

#### **[Awareness, perceived risk and protective behaviours of Myanmar adults on COVID-19](#)**

Kyaw S. Mya, Aye S. M., Win A. Hlaing, Su S. Hlaing, Thida Aung, Swe M. M. Lwin, Ei S. U., Thandar Tun, Kyawt S. Lwin, Hla H. Win

DOI: [10.18203/2394-6040.ijcmph20201530](https://doi.org/10.18203/2394-6040.ijcmph20201530)

#### **[Coverage evaluation of the universal immunization program in Imphal-East district of Manipur: a cross-sectional study](#)**

Dayananda Ingudam, Heisnam Kulabidhu Singh, Longjam Usharani Devi

DOI: [10.18203/2394-6040.ijcmph20201984](https://doi.org/10.18203/2394-6040.ijcmph20201984)

#### **[Knowledge, attitude and practice of fathers about childhood immunization: a tertiary care hospital based cross sectional study](#)**

Swetha E. Jose, Navya C. Joseph, Soorya Sheela, Vidhu M. Joshy

DOI: [10.18203/2394-6040.ijcmph20202008](https://doi.org/10.18203/2394-6040.ijcmph20202008)

*Editorial*

#### **[Introduction of newer vaccines in national immunization programme in India: a challenge](#)**

Ramesh Verma, Vinod Chayal, Meenakshi Kalhan, Rohit Dhaka, Suraj Chawla, Kapil Bhalla

DOI: [10.18203/2394-6040.ijcmph20202021](https://doi.org/10.18203/2394-6040.ijcmph20202021)

### **International Journal of Epidemiology**

Volume 49, Issue Supplement\_1, April 2020

[https://academic.oup.com/ije/issue/49/Supplement\\_1](https://academic.oup.com/ije/issue/49/Supplement_1)

***Big Data, Small Area***

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 12 Issue 5

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/12/iss/5>

[Reviewed earlier]

## **International Journal of Infectious Diseases**

March 2020 Volume 92, Supplement, p1-12, S1-S102

[https://www.ijidonline.com/issue/S1201-9712\(20\)X0004-X](https://www.ijidonline.com/issue/S1201-9712(20)X0004-X)

***Commemorating World Tuberculosis Day March 24th, 2020 : "IT'S TIME TO FIND, TREAT ALL and END TUBERCULOSIS!"***

**[Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?](#)**

Jan-Willem C. Alffenaar, Onno W. Akkerman, Hannah Yejin Kim, Simon Tiberi, Giovanni Battista Migliori

S5–S9

Published online: January 26, 2020

## **JAMA**

April 28, 2020, Vol 323, No. 16, Pages 1529-1626

<http://jama.jamanetwork.com/issue.aspx>

*Original Investigation*

**[Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy](#)**

Giacomo Grasselli, MD; Alberto Zangrillo, MD; Alberto Zanella, MD; et al.

free access has active quiz

JAMA. 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394

This case series describes the demographics, comorbidities, ventilation requirements, dispositions, and mortality of patients with PCR-confirmed SARS-CoV-2 infection admitted to northern Italy ICUs in February-March 2020..

*Preliminary Communication*

**[Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma](#)**

Chenguang Shen, PhD; Zhaoqin Wang, PhD; Fang Zhao, PhD; et al.

free access has active quiz

JAMA. 2020;323(16):1582-1589. doi:10.1001/jama.2020.4783

This case series describes clinical outcomes in 5 Chinese patients with laboratory-confirmed COVID-19, ARDS, and high viral loads despite antiviral treatment who were given human plasma with SARS-CoV-2 antibodies obtained from previously infected and recovered patients.

*Research Letter*

**[Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) From a Symptomatic Patient](#)**

Sean Wei Xiang Ong, MBBS; Yian Kim Tan, PhD; Po Ying Chia, MBBS; et al.

free access has active quiz has audio

JAMA. 2020;323(16):1610-1612. doi:10.1001/jama.2020.3227

This study documents results of SARS-CoV-2 polymerase chain reaction (PCR) testing of environmental surfaces and personal protective equipment surrounding 3 COVID-19 patients in isolation rooms in a Singapore hospital.

### **Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State**

Matt Arentz, MD; Eric Yim, MD; Lindy Klaff, MD; et al.  
free access has audio

JAMA. 2020;323(16):1612-1614. doi:10.1001/jama.2020.4326

This case series describes the clinical presentation, characteristics, and outcomes of patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit at a public hospital in Washington State in February 2020, including initial reports of cardiomyopathy in one-third of the patients.

#### *Viewpoint*

### **Critical Care Utilization for the COVID-19 Outbreak in Lombardy, ItalyEarly Experience and Forecast During an Emergency Response**

Giacomo Grasselli, MD; Antonio Pesenti, MD; Maurizio Cecconi, MD  
free access has active quiz has multimedia has audio

JAMA. 2020;323(16):1545-1546. doi:10.1001/jama.2020.4031

This Viewpoint describes the organization of a regional ICU network in Lombardy, Italy, to handle the surge in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who require intensive care and uses demand experience in the first 2 weeks of the outbreak to estimate resources required in coming weeks.

### **Presidential Powers and Response to COVID-19**

Lawrence O. Gostin, JD; James G. Hodge Jr, JD, LL.M.; Lindsay F. Wiley, JD, MPH  
free access

JAMA. 2020;323(16):1547-1548. doi:10.1001/jama.2020.4335

This Viewpoint reviews legal powers the US president and state governors have to implement travel and other restrictions to control the spread of coronavirus, and discusses the need to balance rights to privacy and liberty with public health in ways that do not disadvantage already vulnerable populations.

### **Managing COVID-19 in Low- and Middle-Income Countries**

Joost Hopman, MD, PhD, DTMH; Benedetta Allegranzi, MD, DTMH; Shaheen Mehtar, MBBS, MD (Lon)

free access has active quiz

JAMA. 2020;323(16):1549-1550. doi:10.1001/jama.2020.4169

This Viewpoint discusses challenges to managing a COVID-19 outbreak in low- and middle-income countries (LMICs), reviewing how absence of testing, critical care capacity, climate, war, distrust, and large refugee populations could complicate implementation of proven infection prevention and control measures.

#### *A Piece of My Mind*

### **Personal Risk and Societal Obligation Amidst COVID-19**

Cynthia Tsai, MD

free access has active quiz

JAMA. 2020;323(16):1555-1556. doi:10.1001/jama.2020.5450

In this narrative medicine essay, a resident physician with asthma describes her internal deliberations about public vs private good after a decision to retreat from direct-patient care to telemedicine to protect her health during the coronavirus pandemic.

*Editorial*

**Critical Illness in Patients With COVID-19****Mounting an Effective Clinical and Research Response**

Deborah J. Cook, MD, MSc; John C. Marshall, MD; Robert A. Fowler, MDCM, MS  
free access has active quiz

JAMA. 2020;323(16):1559-1560. doi:10.1001/jama.2020.5775

**Convalescent Plasma to Treat COVID-19****Possibilities and Challenges**

John D. Roback, MD, PhD; Jeannette Guarner, MD  
free access has active quiz

JAMA. 2020;323(16):1561-1562. doi:10.1001/jama.2020.4940

**JAMA Pediatrics**

April 2020, Vol 174, No. 4, Pages 313-393

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

**JBI Database of Systematic Review and Implementation Reports**

April 2020 - Volume 18 - Issue 4

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

April 2020 Volume 66, Issue 4, p379-514

[https://www.jahonline.org/issue/S1054-139X\(20\)X0003-6](https://www.jahonline.org/issue/S1054-139X(20)X0003-6)

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 67 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 45, Issue 3, June 2020

<https://link.springer.com/journal/10900/45/3>

*Commentary*

**Coronavirus (COVID-19) in Haiti: A Call for Action**

James Louis-Jean, Kenney Cenat, Debbie Sanon, Ruthonce Stvil



*Original Paper*

**Success of an EMR-Driven Postpartum Intervention to Improve HPV Vaccination Rates**

Susan K. Park, Christine H. Holschneider, Judy Chen...

*Original Paper*

**Missed Opportunities for Hepatitis A Vaccination Among MSM Initiating PrEP**

Alwyn Cohall, Jason Zucker, Rachel Krieger, Charlotte Scott...

*Original Paper*

**Cervical Cancer and Human Papillomavirus Vaccine Awareness Among Married Bhutanese Refugee and Nepali Women in Eastern Nepal**

Madhav P. Bhatta, Derek C. Johnson, Mingma Lama...

**Journal of Development Economics**

Volume 144 May 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/144/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 15 Issue 1-2, February-April 2020

<http://journals.sagepub.com/toc/jre/current>

***Special Issue: Ethical Issues in Social Media Research***

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

April 2020 - Volume 74 - 4

<https://jech.bmj.com/content/74/4>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 13, Issue 1 Pages: 1-88 February 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[New issue; No digest content identified]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 31, Number 1, February 2020  
<https://muse.jhu.edu/journal/278>  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 22, Issue 2, April 2020  
<https://link.springer.com/journal/10903/22/2>  
[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 18, 2020\_ Issue 2  
<https://www.tandfonline.com/toc/wimm20/current>  
[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 221, Issue 7, 1 April 2020  
<https://academic.oup.com/jid/issue/221/7>  
[Reviewed earlier]

**Journal of Medical Ethics**

April 2020 - Volume 46 - 4  
<http://jme.bmj.com/content/current>  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 7, Issue 2 (2020)  
<https://digitalrepository.aurorahealthcare.org/jpcrr/>  
[New issue; No digest content identified]

**Journal of Pediatrics**

May 2020 Volume 220, p1-274  
<http://www.jpeds.com/current>  
[New issue; No digest content identified]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>  
[Accessed 2 May 2020]

*Articles*

**[A simplified checklist for the visual inspection of finished pharmaceutical products: a way to empower frontline health workers in the fight against poor-quality medicines](#)**

Authors: B. Schiavetti, E. Wynendaale, V. Melotte, J. Van der Elst, B. De Spiegeleer and R. Ravinetto  
Content type: Short report  
1 May 2020

**Journal of Public Health Management & Practice**

March/April 2020 - Volume 26 - Issue 2  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 41, Issue 1, March 2020  
<https://link.springer.com/journal/41271/41/1>  
[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 2, Issue 2 (2019)  
<https://ir.library.louisville.edu/rgh/>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**

April 2020 Volume 17 Issue 165  
<https://royalsocietypublishing.org/toc/rsif/current>  
[Reviewed earlier]

**Journal of Travel Medicine**

Volume 27, Issue 2, March 2020  
<https://academic.oup.com/jtm/issue/27/2>  
[Reviewed earlier]

**Journal of Virology**

April 2020; Volume 94, Issue 8  
<http://jvi.asm.org/content/current>  
[Reviewed earlier]

**The Lancet**

May 02, 2020 Volume 395 Number 10234 p1401-1460, e75-e82  
<https://www.thelancet.com/journals/lancet/issue/current>  
*Editorial*  
[COVID-19: remaking the social contract](#)  
The Lancet

"Allegiance, after all, has to work two ways; and one can grow weary of an allegiance which is not reciprocal." The British playwright [David Hare quoted](#) this line by the American writer James Baldwin in his recent reflections on the UK Government's response to the coronavirus disease 2019 (COVID-19) pandemic. Baldwin's reminder and warning in the context of civil rights in the mid-20th century USA speak now in the pandemic to communities the world over who are unsure of their governments' allegiances to them. The give-and-take relationship between the state and the individual—perhaps best viewed through the lens of what Enlightenment philosophers termed the social contract—is being strained, its inadequacy exposed, and must surely be remade in the midst of this global health and economic crisis.

Governments now ask heavy sacrifices from their people, with around a third of the global population under some form of lockdown. But demonstration that governments are in fact acting to protect the public, for example, through adequately preparing the health system and giving clear advice aimed at saving lives, has been highly variable. Although international comparisons are not straightforward, there are nonetheless encouraging examples of where strong and swift action has succeeded in staving off the worst effects of the virus, be they Germany's quick escalation of testing, New Zealand's elimination strategy, or South Korea's aggressive pursuit of a test-and-trace approach. By contrast, the UK, USA, and Brazil, among others, have been slow to react and haphazard when they did. The serious deficiencies in pandemic planning and response have sparked protests and condemnation and call into question commitment to the most vital interests of the public.

Such failures have too often been accompanied by poor transparency and an ingrained resistance to all forms of accountability. In March, when US President Donald Trump was asked by a reporter if he takes responsibility for the delay in making test kits available, [he replied](#) "No, I don't take responsibility at all." And in April, at a daily COVID-19 briefing when UK Home Secretary Priti Patel was asked twice if she would apologise about the shortage of personal protective equipment for front-line health-care workers, [she responded](#), "I'm sorry if people feel that there have been failings", in what seemed to be indifference to the sacrifices being made by health-care workers on behalf of the country and its people.

Beyond immediate responses, this pandemic is revealing how a longer-term increase in inequalities and neglect of public services have weakened the ability of societies to deal with external shocks and created new vulnerabilities in a crisis. Racial and ethnic minorities, those with weak employment protections, including migrant workers, and populations without adequate access to affordable health care are among the hardest hit.

However, at the same time, COVID-19 is also overturning core values, norms, and rules that sit at the heart of long-standing market-oriented political agendas. The willingness with which nations have put the brakes on their economies to protect lives, coupled with massive increases in public spending and government debt, particularly by conservative administrations, was inconceivable a few months ago. [According to one analysis](#), as of April 23, a staggering 151 countries have planned, introduced, or adapted a total of 684 social protection measures in response to the pandemic.

Despite important deficiencies in some responses, in many ways the world is witnessing the setting aside of ideology to address the urgent and fundamental need common to all people—the protection of health. So far, the measures taken have been uneven, short-term, and

reactive. But it is hard to imagine that when this pandemic is over, the public will be content to go back to the way things were. That it has taken a crisis of this scale to force the recognition that the basic role of a government is to serve and protect its people—that wellbeing has a higher value than gross domestic product—is a shocking demonstration of how the reciprocal rights and responsibilities that form the basis of so many democratic systems have been hollowed out. The kind of societies that are set to emerge from this pandemic is far from clear, but our interconnectedness and interdependence at local, national, and global levels have never been more undeniable. Nor can the importance of well resourced and well prepared health systems continue to be ignored. A renewed and expanded social contract, one with health at the centre, could well be one legacy of COVID-19.

*Comment*

**Evaluation of a tetravalent dengue vaccine by serostatus and serotype**

Annelies Wilder-Smith

*Comment*

**Ensuring global access to COVID-19 vaccines**

Gavin Yamey, Marco Schäferhoff, Richard Hatchett, Muhammad Pate, Feng Zhao, Kaci Kennedy McDade

The current response to the coronavirus disease 2019 (COVID-19) pandemic involves aggressive implementation of suppression strategies, such as case identification, quarantine and isolation, contact tracing, and social distancing. However, models developed by the Imperial College COVID-19 Response Team suggest that “transmission will quickly rebound if interventions are relaxed”.<sup>1</sup> WHO warns of multiple simultaneous outbreaks of COVID-19 worldwide.<sup>2</sup> The development of COVID-19 vaccines that can be used globally is therefore a priority for ending the pandemic.

This vaccine effort should be guided by three imperatives: speed, manufacture and deployment at scale, and global access. In February, 2020, the World Bank and the Coalition for Epidemic Preparedness Innovations (CEPI), which funds development of epidemic vaccines, co-hosted a global consultation on these goals.<sup>3</sup> This consultation led to the launch of a COVID-19 Vaccine Development Taskforce that is now working on how to finance and manufacture vaccines for global access.

CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US\$2 billion.<sup>4</sup> This estimate includes phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines. This estimate does not include the costs of manufacture or delivery. Progress has been rapid. A phase 1 trial of a vaccine candidate, supported by the US National Institutes of Health and CEPI, began on March 16, 2020,<sup>5</sup> and 2 days later a clinical trial began in China.<sup>6</sup> Clinical trials for other candidates will start soon.

Use of existing financing systems to support this work offers the benefits of speed and lower transaction costs than for new financing approaches. CEPI is supported by a World Bank financial intermediary fund that brings together public, philanthropic, and private funding to respond to global priorities.<sup>7</sup> Through this fund, CEPI can act as a global mechanism for

funding vaccine development until vaccines can be licensed or used under emergency use provisions. Mobilising \$2 billion in funding will require funding from all sources. Given the enormous health, social, and economic consequences of COVID-19, there is a strong case for all governments to invest in vaccines.

In addition to direct government contributions, innovative finance mechanisms have been successful in raising funds for vaccines in the past and should be used to fund the development of COVID-19 vaccines.<sup>8, 9</sup> The International Finance Facility for Immunisation (IFFIm) raises funds with vaccine bonds, which turn long-term contributions by donors into available cash.<sup>8</sup> IFFIm was created to support Gavi, the Vaccine Alliance, but could be used to finance CEPI's COVID-19 vaccine efforts. With advanced market commitments, donors make funding commitments to vaccine manufacturers and, in exchange, companies sign a legally binding commitment to provide the vaccines at a price affordable to low-income and middle-income countries. Gavi's board expressed support for the use of Gavi's IFFIm and advanced market commitments to improve COVID-19 vaccine development and access.<sup>10</sup>

The need for COVID-19 vaccines is global, although the need is differentially distributed within populations. Vaccines would likely be prioritised for health-care workers and people at greatest risk of severe illness and death. High-income countries must not monopolise the global supply of COVID-19 vaccines. This risk is real: during the 2009 influenza A/H1N1 pandemic, rich countries negotiated large advance orders for the vaccine, crowding out poor countries.<sup>11</sup> Such an outcome would result in a suboptimal allocation of an initially scarce resource.

#### *Articles*

##### **Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial**

Shibadas Biswal, et al for the TIDES study group

A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naïve and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4–16 years.

##### **Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial**

Vianney Tricou, et al

An unmet clinical need remains for an effective tetravalent dengue vaccine suitable for all age groups, regardless of serostatus. We assessed the immunogenicity and safety of three different dose schedules of a tetravalent dengue vaccine (TAK-003) over a 48-month period in children living in dengue-endemic countries.

#### **The Lancet Child & Adolescent Health**

May 2020 Volume 4 Number 5 p341-406, e10-e11

<https://www.thelancet.com/journals/lanchi/issue/current>

#### *Comment*

##### **Prioritisation of the human papillomavirus vaccine in a time of constrained supply**

Aimée R Kreimer, Tania Cernuschi, Helen Rees, Debbie Saslow, Carolina Porras, John Schiller

## **Lancet Digital Health**

May 2020 Volume 2 Number 5 e209-e267

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

## **Lancet Global Health**

May 2020 Volume 8 Number 5 e612-e736

<http://www.thelancet.com/journals/langlo/issue/current>

*Editorial*

### **[Decolonising COVID-19](#)**

The Lancet Global Health

## **Lancet Infectious Diseases**

May 2020 Volume 20 Number 5 p511-628, e79-e115

<http://www.thelancet.com/journals/laninf/issue/current>

*Editorial*

### **[COVID-19: endgames](#)**

The Lancet Infectious Diseases

*Articles*

### **[Early dynamics of transmission and control of COVID-19: a mathematical modelling study](#)**

Adam J Kucharski, et al. on behalf of the Centre for Mathematical Modelling of Infectious Diseases COVID-19 working group

Open Access

### **[Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study](#)**

Nan Yu, et al.

### **[Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study](#)**

Kelvin Kai-Wang To, et al.

*Review*

### **[The state of vaccine safety science: systematic reviews of the evidence](#)**

Matthew Z Dudley, Neal A Halsey, Saad B Omer, Walter A Orenstein, Sean T O'Leary, Rupali J Limaye, Daniel A Salmon

*Summary*

This Review updates the scientific evidence assessing possible causal associations of adverse events following immunisation (AEFI) compiled in the 2012 report from the Institute of Medicine and the 2014 report from the Agency for Healthcare Research and Quality. For 12 of 46 AEFI examined, a causal relationship has been established with at least one vaccine currently routinely recommended to the general USA population: anaphylaxis, arthralgia or arthritis (mild, acute, and transient, not chronic), deltoid bursitis (when vaccine is administered improperly),

disseminated varicella infection (in immune deficient individuals for whom the varicella vaccine is contraindicated), encephalitis, febrile seizures, Guillain-Barré syndrome, hepatitis (in immune deficient individuals for whom the varicella vaccine is contraindicated), herpes zoster, immune thrombocytopenic purpura, meningitis, and syncope. Other than mild acute and transient arthralgia or arthritis, which is very common in adult women after rubella vaccine, these adverse reactions are rare or very rare. Vaccines have an excellent safety profile overall and provide protection against infectious diseases to individuals and the general population.

### **Lancet Public Health**

Apr 2020 Volume 5 Number 4 e177-e234

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

### **Lancet Respiratory Medicine**

Apr 2020 Volume 8 Number 4 p321-422, e14-e26

<http://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 24, Issue 5, May 2020

<https://link.springer.com/journal/10995/24/5>

[New issue; No digest content identified]

### **Medical Decision Making (MDM)**

Volume 40 Issue 2, February 2020

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 98, Issue 1 Pages: 1-222 March 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

### **Nature**

Volume 580 Issue 7805, 30 April 2020

[http://www.nature.com/nature/current\\_issue.html](http://www.nature.com/nature/current_issue.html)

*Editorial* | 29 April 2020

#### **[Show evidence that apps for COVID-19 contact-tracing are secure and effective](#)**

Governments see coronavirus apps as key to releasing lockdowns. In exchange for people's health data, they must promise to work together to develop the highest standards of safety and efficacy.



**Nature Biotechnology**

Volume 38 Issue 4, April 2020

<https://www.nature.com/nbt/volumes/38/issues/4>

[Reviewed earlier]

**Nature Genetics**

Volume 52 Issue 4, April 2020

<https://www.nature.com/ng/volumes/52/issues/4>

[Reviewed earlier]

**Nature Medicine**

Volume 26 Issue 4, April 2020

<https://www.nature.com/nm/volumes/26/issues/4>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 21 Issue 5, May 2020

<https://www.nature.com/nrg/volumes/21/issues/5>

[New issue; No digest content identified]

**Nature Reviews Immunology**

Volume 20 Issue 5, May 2020

<https://www.nature.com/nri/volumes/20/issues/5>

[New issue; No digest content identified]

**Nature Reviews Drug Discovery**

Volume 19 Issue 4, April 2020

<https://www.nature.com/nrd/volumes/19/issues/4>

[Reviewed earlier]

**New England Journal of Medicine**

April 30, 2020 Vol. 382 No. 18

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

**[Responding to Covid-19 — A Once-in-a-Century Pandemic?](#)**

Bill Gates

In any crisis, leaders have two equally important responsibilities: solve the immediate problem and keep it from happening again. The Covid-19 pandemic is a case in point. We need to save lives now while also improving the way we respond to outbreaks in general. The first point is more pressing, but the second has crucial long-term consequences.

The long-term challenge — improving our ability to respond to outbreaks — isn't new. Global health experts have been saying for years that another pandemic whose speed and severity rivaled those of the 1918 influenza epidemic was a matter not of if but of when.<sup>1</sup> The Bill and Melinda Gates Foundation has committed substantial resources in recent years to helping the world prepare for such a scenario.

Now we also face an immediate crisis. In the past week, Covid-19 has started behaving a lot like the once-in-a-century pathogen we've been worried about. I hope it's not that bad, but we should assume it will be until we know otherwise...

## **Pediatrics**

Vol. 145, Issue 5 1 May 2020

<https://pediatrics.aappublications.org/>

### *Articles*

#### **Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates**

Peter Szilagyi, Christina Albertin, Dennis Gurfinkel, Brenda Beaty, Xinkai Zhou, Sitaram Vangala, John Rice, Jonathan D. Campbell, Melanie D. Whittington, Rebecca Valderrama, Abigail Breck, Heather Roth, Megan Meldrum, Chi-Hong Tseng, Cynthia Rand, Sharon G. Humiston, Stanley Schaffer, Allison Kempe

Pediatrics, May 2020, 145 (5) e20192689

#### **Use of Standing Orders for Vaccination Among Pediatricians**

Jessica Cataldi, Sean T. O'Leary, Megan C. Lindley, Mandy A. Allison, Laura P. Hurley, Lori A. Crane, Michaela Brtnikova, Brenda Beaty, Erin McBurney, Allison Kempe

Pediatrics, May 2020, 145 (5) e20191855

### *Commentaries*

#### **Optimizing Human Papillomavirus Immunization: The Role of Centralized Reminder and Recall Systems**

Sarah Geoghegan, Kristen Feemster

Pediatrics, May 2020, 145 (5) e20193596

## **Pharmaceutics**

Volume 12, Issue 3 (March 2020)

<https://www.mdpi.com/1999-4923/12/3>

[Reviewed earlier]

## **PharmacoEconomics**

Volume 38, Issue 5, May 2020

<https://link.springer.com/journal/40273/38/5>

[New issue; No digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 2 May 2020)  
[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 2 May 2020)

#### **[Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks](#)**

The PLOS Medicine Editors

Editorial | published 28 Apr 2020 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003123>

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 2 May 2020)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 2 May 2020]

#### **[Exploring factors improving support for vaccinations among Polish primary care physicians](#)**

Pawel Stefanoff, Tomasz Sobierajski, Helena Bulinska-Stangrecka, Ewa Augustynowicz

Research Article | published 01 May 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0232722>

#### **[Willingness to pay for oral cholera vaccines in urban Bangladesh](#)**

Abdur Razzaque Sarker, Ziaul Islam, Marufa Sultana, Nurnabi Sheikh, Rashidul Alam Mahumud, Md. Taufiqul Islam, Robert Van Der Meer, Alec Morton, Ashraful Islam Khan, John David Clemens, Firdausi Qadri, Jahangir A. M. Khan

Research Article | published 30 Apr 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0232600>

#### **[Evidence of rotavirus vaccine impact in sub-Saharan Africa: Systematic review and meta-analysis](#)**

Opolot Godfrey, Weidong Zhang, Cecilia Amponsem-Boateng, Timothy Bonney Oppong, QingLin Zhao, Dankang Li

Research Article | published 27 Apr 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0232113>

#### **[Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis](#)**

Ravi Potluri, Amit Kumar, Vikalp Maheshwari, Charlie Smith, Valerie Oriol Mathieu, Kerstin Luhn, Benoit Callendret, Hitesh Bhandari

Research Article | published 27 Apr 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0230406>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 2 May 2020]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States of America**

<http://www.pnas.org/content/early/>

[Accessed 2 May 2020]

[No new digest content identified]

### **Prehospital & Disaster Medicine**

Volume 35 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 133 April 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/133/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

08 April 2020 Volume 287 Issue 1924

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

### **Public Health**

Volume 181 Pages 1-204 (April 2020)

<https://www.sciencedirect.com/journal/public-health/vol/181/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 12, Issue 3, November 2019

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Reports**

Volume 135 Issue 2, March/April 2020

<https://journals.sagepub.com/toc/phrg/135/2>  
[Reviewed earlier]

### **Qualitative Health Research**

Volume 30 Issue 5, April 2020  
<http://qhr.sagepub.com/content/current>  
[New issue; No digest content identified]

### **Research Ethics**

Volume 15 Issue 3-4, July-October 2019  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 2 May 2020]  
[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest articles*

27 Apr 2020

[\*\*COVID-19 and newborn health: systematic review\*\*](#)

*Review*

### **Risk Analysis**

Volume 40, Issue 4 Pages: 657-898 April 2020  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[New issue; no digest content identified]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[Accessed 2 May 2020]  
[No new digest content identified]

### **Science**

01 May 2020 Vol 368, Issue 6490  
<http://www.sciencemag.org/current.dtl>  
*Editorial*  
[\*\*COVID-19 amidst Ebola's retreat\*\*](#)

By John Ditekemena

01 May 2020

### *Summary*

In April, the Democratic Republic of the Congo (DRC) was on the verge of good news—announcing an end to its tenth (and the world's second largest) Ebola outbreak. Unfortunately, since 10 April, new Ebola cases have been reported in Beni, the epicenter of the Ebola outbreak. Although the DRC has long struggled with political unrest, armed conflict, poverty, and infectious diseases, it must remain committed to ending the Ebola crisis while also applying the lessons learned in tackling this old viral enemy to combat a new one—severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19).

### *Policy Forum*

#### **Against pandemic research exceptionalism**

By Alex John London, Jonathan Kimmelman

Science01 May 2020 : 476-477 Full Access

*Crises are no excuse for lowering scientific standards*

### *Summary*

The global outbreak of coronavirus disease 2019 (COVID-19) has seen a deluge of clinical studies, with hundreds registered on [clinicaltrials.gov](https://clinicaltrials.gov). But a palpable sense of urgency and a lingering concern that “in critical situations, large randomized controlled trials are not always feasible or ethical” (1) perpetuate the perception that, when it comes to the rigors of science, crisis situations demand exceptions to high standards for quality. Early phase studies have been launched before completion of investigations that would normally be required to warrant further development of the intervention (2), and treatment trials have used research strategies that are easy to implement but unlikely to yield unbiased effect estimates. Numerous trials investigating similar hypotheses risk duplication of effort, and droves of research papers have been rushed to preprint servers, essentially outsourcing peer review to practicing physicians and journalists. Although crises present major logistical and practical challenges, the moral mission of research remains the same: to reduce uncertainty and enable caregivers, health systems, and policy-makers to better address individual and public health. Rather than generating permission to carry out low-quality investigations, the urgency and scarcity of pandemics heighten the responsibility of key actors in the research enterprise to coordinate their activities to uphold the standards necessary to advance this mission.

Research Articles

#### **Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)**

By Ruiyun Li, Sen Pei, Bin Chen, Yimeng Song, Tao Zhang, Wan Yang, Jeffrey Shaman

Science01 May 2020 : 489-493 Open Access [CCBY](https://www.sciencemag.org/doi/10.1126/science.abb3221)

Prior to travel restrictions, most SARS-CoV-2 infections went undocumented and substantially contributed to global virus spread.

### **Science Translational Medicine**

29 April 2020 Vol 12, Issue 541

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 251 April 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/249/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 2 May 2020]

[No new digest content identified]

### **Travel Medicine and Infectious Diseases**

Volume 33 January–February 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/33/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 25, Issue 4 Pages: i-iv, 387-505 April 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 38, Issue 20 Pages 3627-3698 (29 April 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/20>

*Research article Open access*

[\*\*Childhood vaccination coverage and equity impact in Ethiopia by socioeconomic, geographic, maternal, and child characteristics\*\*](#)

Anne Geweniger, Kaja M. Abbas

Pages 3627-3638

*Research article Open access*

[\*\*Effect of a school-based educational intervention on HPV and HPV vaccine knowledge and willingness to be vaccinated among Chinese adolescents : a multi-center intervention follow-up study\*\*](#)

Xi Zhang, Chun-rong Liu, Zeng-zhen Wang, Ze-fang Ren, ... Jing Li

Pages 3665-3670

### **Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

(Accessed 2 May 2020)

[No new digest content identified]

## **Value in Health**

April 2020 Volume 23, Issue 4, p409-526

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0005-2](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0005-2)

*THEMED SECTION: VALUE-BASED CONTRACTING*

[Reviewed earlier]

\* \* \* \*

## **From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary**

### **Cognitive Processing**

Published: 24 April 2020

#### **The effects of source expertise and trustworthiness on recollection: the case of vaccine misinformation**

S Pluviano, S Della Sala, C Watt

##### *Abstract*

Designing effective communication strategies for correcting vaccines misinformation requires an understanding of how the target group might react to information from different sources. The present study examined whether erroneous inferences about vaccination could be effectively corrected by a perceived credible (i.e. expert or trustworthy) source. Two experiments are reported using a standard continued influence paradigm, each featuring two correction conditions on vaccine misinformation. Participants were presented with a story containing a piece of information that was later retracted by a perceived credible or not so credible source. Experiment 1 showed that providing a correction reduced participants' use of the original erroneous information, yet the overall reliance on misinformation did not significantly differ between the low- and high-expertise correction groups. Experiment 2 revealed that a correction from a high-trustworthy source decreased participants' reliance on misinformation when making inferences; nonetheless, it did not positively affect the reported intent to vaccinate one's child. Overall, source trustworthiness was more relevant than source expertise.

### **Journal of Pediatric Nursing**

Available online 27 April 2020

#### **Parents' perspectives about vaccine hesitancies and vaccine rejection, in the west of Turkey**

NA Gunes

##### *Highlights*

- :: Vaccination services are carried out in primary health care institutions.
- :: Vaccine rejection is a significant public health problem.
- :: Regional assessments in countries on vaccine rejection are crucial.

### **European Journal of Epidemiology**



2020 Apr 22 : 1–6.

### **Vaccine confidence in the time of COVID-19**

EA Harrison, JW Wu -, 2020

#### *Abstract*

In the early months of the COVID-19 epidemic, some have wondered if the force of this global experience will solve the problem of vaccine refusal that has vexed and preoccupied the global public health community for the last several decades. Drawing on historical and epidemiological analyses, we critique contemporary approaches to reducing vaccine hesitancy and articulate our notion of vaccine confidence as an expanded way of conceptualizing the problem and how to respond to it. Intervening on the rush of vaccine optimism we see pervading present discourse around the COVID-19 epidemic, we call for a re-imagination of the culture of public health and the meaning of vaccine safety regulations. Public confidence in vaccination programs depends on the work they do for the community—social, political, and moral as well as biological. The concept of public health and its programs must be broader than the delivery of the vaccine technology itself. The narrative work and policy actions entailed in actualizing such changes will, we expect, be essential in achieving a true vaccine confidence, however the public reacts to the specific vaccine that may be developed for COVID-19

\*

\*

\*

\*

### **Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

#### **The Atlantic**

<http://www.theatlantic.com/magazine/>

Accessed 2 May 2020

Coronavirus: COVID-19

#### **I Have Seen the Future—And It's Not the Life We Knew**

*Cities around the world might slowly be coming back to life, but there's no going back to "normal."*

Uri Friedman May 1, 2020

#### **BBC**

<http://www.bbc.co.uk/>

Accessed 2 May 2020

*Technology*

**Coronavirus: Cyber-spies seek coronavirus vaccine secrets**

By Gordon Corera Security correspondent

The US has seen foreign spy agencies carry out reconnaissance of research into a coronavirus vaccine, a senior US intelligence official has told the BBC.

Bill Evanina, director of the National Counterintelligence and Security Center, said the US government had warned medical research organisations of the risks.

But he would not say whether there had been confirmed cases of stolen data.  
UK security sources says they have also seen similar activity...

**The Economist**

<http://www.economist.com/>

*Accessed 2 May 2020*

[No new, unique, relevant content]

**Financial Times**

<http://www.ft.com/home/uk>

*Accessed 2 May 2020*

[No new, unique, relevant content]

**Forbes**

<http://www.forbes.com/>

May 1, 2020

**For Retail To Survive COVID-19 We Must All Face The Biggest Taboo Of The 21st Century**

One consequence of the COVID-19 pandemic is that death is conveyed into our homes on a daily basis.

By Andrew Busby Contributor

Apr 30, 2020

**Lessons From Ebola: It's Not Enough To Fight One Disease Outbreak - You Have To Build Systems That Can Prevent The Next Ones**

The COVID-19 pandemic is an unparalleled example of systems failure, with adverse impacts on education, health and economic opportunity.

By Raj Panjabi Contributor

**Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 2 May 2020*

*Snapshot April 30, 2020*

**Finding a Vaccine Is Only the First Step**

*No One Will Be Safe Until the Whole World Is Safe*

As scientists race to develop a coronavirus vaccine, the international community must remember that the ultimate goal is not only to produce an effective inoculation but...

Ngozi Okonjo-Iweala

**Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 2 May 2020 |*

*Argument*

### **Why Herd Immunity Won't Save India From COVID-19**

By Devi Sridhar, Genevieve Fernandes

| May 2, 2020, 2:00 AM

Rather than relying on mass infection to build resistance to the coronavirus, the country needs a long-term, data-driven, decentralized approach.

### **The Guardian**

<http://www.guardiannews.com/>

*Accessed 2 May 2020*

[No new, unique, relevant content]

### **New Yorker**

<http://www.newyorker.com/>

*Accessed 2 May 2020*

[No new, unique, relevant content]

### **New York Times**

<http://www.nytimes.com/>

*Accessed 2 May 2020*

U.S.

### **Anti-Vaccination Activists Are Growing Force at Virus Protests**

Public health experts fear that their messaging could further harm the country's response to the pandemic.

By Nicholas Bogel-Burroughs

*Opinion*

### **She Predicted the Coronavirus. What Does She Foresee Next?**

Laurie Garrett, the prophet of this pandemic, expects years of death and "collective rage."

By Frank Bruni

Opinion Columnist

May 2, 2020,

*Politics*

### **Profits and Pride at Stake, the Race for a Vaccine Intensifies**

Governments, companies and academic labs are accelerating their efforts amid geopolitical crosscurrents, questions about safety and the challenges of producing enough doses for billions of people.

By David E. Sanger, David D. Kirkpatrick, Carl Zimmer, Katie Thomas and Sui-Lee Wee

*Politics*

### **WH Blocking Fauci Testimony to House Panel, Spokesman Says**

A spokesman for a key House panel said Friday that the White House has blocked Dr. Anthony Fauci from testifying next week at a hearing on the coronavirus outbreak.

By The Associated Press

### **Washington Post**

<https://www.washingtonpost.com/>

*Accessed 2 May 2020*

**[Inside the extraordinary race to invent a coronavirus vaccine](#)**

Carolyn Y. Johnson · Science · May 2, 2020

**[The last time the government sought a 'warp speed' vaccine, it was a fiasco](#)**

Michael S. Rosenwald · Retropolis · May 1, 2020

**[UN: New polio outbreak in Niger after vaccination suspended](#)**

Apr 29, 2020

\*

\*

\*

\*

**[Think Tanks et al](#)**

**Brookings**

<http://www.brookings.edu/>

*Accessed 2 May 2020*

*TechStream*

**[Can artificial intelligence help us design vaccines?](#)**

Ethan Fast and Binbin Chen

Thursday, April 30, 2020

**Center for Global Development** [to 2 May 2020]

<http://www.cgdev.org/page/press-center>

*Accessed 2 May 2020*

May 1, 2020

**[Accountability for COVID-19 Aid: Better Visibility Matters for the Quality of the Response](#)**

As low- and middle-income countries are hit by the health and economic effects of COVID-19, the international community is working to mobilize billions of dollars in grants, loans, and debt relief. At the moment, it is difficult to get a full picture of the funding on offer, to whom it is given, and how it will be used.

Janeen Madan Keller, [Julia Kaufman](#) and [Amanda Glassman](#)

April 29, 2020

**[Maintaining Essential Services in the Time of COVID-19: Vaccination Delivery in Low- and Middle-Income Countries](#)**

As we observe [World Immunisation Week](#), the implications of COVID-19's spread for routine childhood vaccination delivery are already becoming clear.

[Sharif Ismail](#) et al.

**[Delivering on the Promise of "Equitable Access" to Epidemic Vaccines and Treatments: the Need for Norms, Processes, and Evidence to Guide Supply and Allocation](#)**

Publication

4/25/20

While there has been much interest and investment in developing epidemic vaccines and medicines to combat emerging infectious disease threats, there has been less attention to how we will manage and allocate the global supply of efficacious vaccines and treatments once we have them. The launch of the Access to COVID-19 Tools (ACT) Accelerator marks an unprecedented commitment to global collaboration to ensure rapid and equitable access to medical countermeasures for COVID-19, such as vaccines and treatments.

## **CSIS**

<https://www.csis.org/>

*Accessed 2 May 2020*

*Commentary*

### **How Covid-19 Will Change Us: Seven Lessons from the Most Consequential Pandemics in History**

April 29, 2020 | By [Iain King](#)

*Commentary*

### **WHO and President Trump on the Ledge**

April 28, 2020 | By [J. Stephen Morrison](#), [Anna Carroll](#)

*Commentary*

### **Gender and Immunizations within the Covid-19 Landscape**

April 27, 2020 | By [Katherine Bliss](#)

## **Council on Foreign Relations**

<http://www.cfr.org/>

*Accessed 2 May 2020*

[No new relevant content]

## **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Accessed 2 May 2020*

[No new relevant content]

*	*	*	*
*	*	*	*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

*CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].*

*Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

*	*	*	*
*	*	*	*